Morgan Stanley Maintains Overweight on ArcBest, Raises Price Target to $180

Benzinga Newsdesk www.benzinga.com Positive 71.4%

Neg 0% Neu 0% Pos 71.4%

Morgan Stanley analyst Ravi Shanker maintains ArcBest (NASDAQ:ARCB) with a Overweight and raises the price target from $150 to $180.